Medicenna Q3 2019 Corporate Overview - MDNA55 Clinical Data

Medicenna presents Q3 2019 corporate overview highlighting MDNA55, an IL-4R-targeted therapy for glioblastoma (GBM) with Phase 2b trial enrollment completed and orphan drug designation. The presentation details the company's SuperKine platform technology, clinical efficacy data in 112 recurrent GBM patients, and a projected $2 billion market opportunity for brain cancer treatments.